Implementing Evidence-Based Pain Management Interventions Into an Emergency Department: Outcomes Guided by Use of the Ottawa Model of Research Use.

Aim: To implement strategies to improve the care of patients with acute pain in the emergency department (ED).

Design: Pre-post implementation study using a Type 2 hybrid effectiveness-implementation design.

Methods: Implementation strategies were introduced and monitored through the Ottawa Model of Research Uses' assessment, monitoring and evaluation cycles, supported by focused and sustained facilitation.

Association between insomnia and four domains of health based on an Indigenous Medicine Wheel: Findings from two Saskatchewan First Nation communities.

Objectives: Research has shown that insomnia and chronic diseases can simultaneously impact overall health, including physical, mental, emotional, and spiritual health. This study aims to find the association between insomnia and the four domains of health based on an Indigenous Medicine Wheel and to find the role of multimorbidity as a mediator between this relation among First Nations people.

Methods: We used data (n = 588) from the First Nations Sleep Health Project, a collaboration between two Cree First Nations communities in Saskatchewan and a research team at the University of Saskatchewan.

Adaptive interventions for advancing in situ wildlife disease management.

There is a critical need for advancements in disease management strategies for wildlife, but free-living animals pose numerous challenges that can hinder progress. Most disease management attempts involve fixed interventions accompanied by post hoc outcome assessments focused on success or failure. Though these approaches have led to valuable management advances, there are limitations to both the rate of advancement and amount of information that can be gained.

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Importance: Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these targets with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has not yet been evaluated in a randomized clinical trial.

Objective: To evaluate the 52-week safety and efficacy of lerodalcibep, a small anti-PCSK9-binding protein, in patients with cardiovascular disease (CVD) or who are at very high or high risk of CVD and requiring addition LDL-C-lowering treatment.